India Approves First Dengue Vaccine QDENGA
Current Affairs + Static GK + Exam Tricks + 10 Clickable MCQs
Useful for UPSC, APPSC, TSPSC, SSC, Railway, Banking, Police SI and Constable examinations.
Current Update Explained
QDENGA is a live-attenuated, tetravalent dengue vaccine developed by Japan-based Takeda. A live-attenuated vaccine uses weakened forms of a pathogen to stimulate an immune response, while “tetravalent” means the formulation is designed to cover all four recognised dengue-virus serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. WHO explains that TAK-003 uses a DENV-2 strain as the genomic backbone. The vaccination course consists of two subcutaneous doses administered three months apart.
The approval is important for current-affairs examinations because it connects public health, virology, vaccines, Indian drug regulation and international institutions. However, regulatory approval should not be confused with automatic inclusion in India’s Universal Immunisation Programme. Any public rollout, target group, pricing, procurement and implementation plan depends on subsequent government and health-authority decisions.
QDENGA: Important Facts Table
| Exam Point | Correct Fact |
|---|---|
| Commercial name | QDENGA |
| Development code | TAK-003 |
| Developer | Takeda |
| Indian regulator | Drug Controller General of India (DCGI) |
| Type | Live-attenuated tetravalent dengue vaccine |
| Serotypes targeted | DENV-1, DENV-2, DENV-3 and DENV-4 |
| Genomic backbone | DENV-2 strain |
| Reported India indication | Prevention of dengue disease in individuals aged 4–60 years |
| Dose schedule | Two doses, three months apart |
| Route | Subcutaneous injection |
| WHO prequalification | Effective from 9 May 2024 |
| Indian manufacturing partner | Biological E. Limited |
- India’s reported regulatory approval: ages 4–60 years.
- WHO’s current programmatic recommendation: children aged 6–16 years in settings with high dengue-transmission intensity.
- Regulatory approval does not by itself mean that the vaccine has been added to a national routine-immunisation programme.
Dengue Static GK for Competitive Exams
| Topic | Exam Fact |
|---|---|
| Disease type | Mosquito-borne viral disease |
| Causative agent | Dengue virus (DENV) |
| Virus group | Genus Flavivirus, family Flaviviridae |
| Principal vector | Aedes aegypti |
| Other important vector | Aedes albopictus |
| Biting behaviour | Mostly active during daytime, especially early morning and before dusk |
| Number of serotypes | Four: DENV-1 to DENV-4 |
| Specific antiviral treatment | No specific antiviral treatment; timely supportive clinical care is important |
| Prevention | Vector control, removal of stagnant water, personal protection and vaccination where officially recommended |
Why Can a Second Infection Be More Serious?
Infection with one dengue serotype gives long-term protection mainly against that same serotype, but protection against the other serotypes is limited and temporary. A later infection with a different serotype can carry a greater risk of severe dengue. This is one reason dengue-vaccine development is scientifically complex and why exam questions often focus on the four-serotype concept.
DCGI and CDSCO: Static Polity–Administration Link
- CDSCO: Central Drugs Standard Control Organization.
- Administrative location: Directorate General of Health Services, Ministry of Health and Family Welfare.
- DCGI: Drugs Controller General of India.
- Important function: central approval of new drugs, clinical trials and specified products including vaccines and sera.
WHO Prequalification and Manufacturing Link
WHO’s vaccine-prequalification database lists QDENGA as a dengue tetravalent live-attenuated vaccine with prequalification effective from 9 May 2024. Prequalification helps international procurement agencies assess whether a vaccine meets relevant standards for quality, safety and efficacy.
Takeda and Hyderabad-based Biological E. announced a manufacturing partnership in 2024. Biological E. planned capacity of up to 50 million doses per year, supporting Takeda’s broader objective of producing 100 million doses annually by the end of the decade. This is useful for questions connecting global health with India’s vaccine-manufacturing sector.
“Q–4–2–3”
QDENGA → protects against 4 dengue serotypes → given in 2 doses → 3 months apart.
Most Important Exam Traps
Quick Revision Points
- India’s first approved dengue vaccine: QDENGA.
- Development code: TAK-003.
- Approval authority: DCGI.
- Developer: Takeda of Japan.
- Vaccine type: live-attenuated tetravalent.
- Serotypes: DENV-1, DENV-2, DENV-3 and DENV-4.
- Genomic backbone: DENV-2.
- Reported Indian approval age: 4–60 years.
- Dose schedule: two doses, three months apart.
- Principal vector: Aedes aegypti.
- WHO prequalification: 9 May 2024.
- Indian manufacturing partner: Biological E. Limited, Hyderabad.
10 MCQs
1. Which vaccine became the first dengue vaccine to receive market authorisation in India in July 2026?
2. Which authority granted market authorisation to QDENGA in India?
3. QDENGA is best described as which type of vaccine?
4. How many major dengue-virus serotypes are recognised?
5. What is the standard QDENGA schedule described by WHO?
6. The principal mosquito vector of dengue is:
7. WHO currently recommends programmatic use of TAK-003 mainly for which group in high-transmission settings?
8. QDENGA received WHO prequalification in:
9. Which dengue strain is used as the genomic backbone of TAK-003?
10. Which statement about dengue prevention is correct?
Frequently Asked Questions
Is QDENGA the first dengue vaccine approved in India?
Yes. The July 2026 market authorisation made QDENGA the first dengue vaccine approved in India.
Does QDENGA target all four dengue serotypes?
It is a tetravalent live-attenuated vaccine designed to target DENV-1, DENV-2, DENV-3 and DENV-4.
Is prior dengue testing required before QDENGA?
Reports on India’s approval state that it may be administered irrespective of previous dengue exposure and does not require routine pre-vaccination screening. Actual administration must follow the approved Indian label and medical advice.
Does WHO recommend it for everyone aged 4–60?
No. WHO’s current programmatic recommendation focuses on children aged 6–16 years in high-transmission settings. This is different from the broader age range reported in India’s regulatory approval.
Can vaccination replace mosquito control?
No. WHO says vaccination should form part of an integrated dengue-control strategy that also includes vector control, case management, education and community participation.
Related Learn With Mahesh Links
- World Health Day – WHO Static GK & MCQs
- National Science Day – Science GK & MCQs
- Important Days and Dates Master Hub
- Learn With Mahesh – Competitive Exam Preparation
Sources and References
- Reuters – QDENGA becomes first dengue vaccine approved in India, 20 July 2026
- WHO – Vaccines and immunization: Dengue
- WHO Prequalification – QDENGA product overview
- WHO – Dengue fact sheet
- CDSCO – Functions of CDSCO and DCGI
- Biological E. – Manufacturing collaboration with Takeda
Last fact-checked: 20 July 2026.
Comments
Post a Comment